Prelude Capital Management, LLC Akebia Therapeutics, Inc. Transaction History

Prelude Capital Management, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 16, 2021	SELL	$2.22 - $3.78 $68,571 - $116,756	-30,888 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$2.39 - $13.08 $73,822 - $404,015	30,888 New	30,888 $78,000
Q3 2019 Nov 14, 2019	SELL	$3.55 - $5.4 $4,998 - $7,603	-1,408 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$4.1 - $8.05 $5,772 - $11,334	1,408 New	1,408 $7,000
Q1 2019 May 15, 2019	SELL	$5.41 - $8.73 $3,024 - $4,880	-559 Closed	0 $0
Q4 2018 Feb 14, 2019	SELL	$5.39 - $9.15 $1,158 - $1,967	-215 Reduced 27.78%	559 $3,000
Q3 2018 Nov 14, 2018	SELL	$7.44 - $10.65 $47,296 - $67,702	-6,357 Reduced 89.15%	774 $7,000
Q2 2018 Aug 14, 2018	SELL	$9.15 - $11.34 $48,055 - $59,557	-5,252 Reduced 42.41%	7,131 $71,000
Q1 2018 May 15, 2018	BUY	$9.53 - $15.68 $118,009 - $194,165	12,383 New	12,383 $118,000

110

55.3M

554K

246K

Ticker AKBA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 183,848,992
Market Cap $268M
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Prelude Capital Management, LLC with notifications on news.